Co-administration of Lactobacillus gasseri KBL697 and tumor necrosis factor-alpha inhibitor infliximab improves colitis in mice

• Published in: Scientific reports Vol. 12; no. 1; pp. 9640 - 9
• Main Authors: Han, Dae Hee, Kim, Woon-ki, Lee, Cheonghoon, Park, SungJun, Lee, Kiuk, Jang, Sung Jae, Ko, GwangPyo
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 10.06.2022; Nature Publishing Group; Nature Portfolio
• Subjects: 631/250; 631/326; 692/700; Acetic acid; Animals; Body weight; CD25 antigen; CD4 antigen; Cecum; Colitis; Colitis - chemically induced; Colitis - drug therapy; Colitis - metabolism; Colon - pathology; Combined treatment; Cytokines - metabolism; Dextran; Dextran Sulfate - toxicity; Disease Models, Animal; Female; Foxp3 protein; Gastrointestinal tract; Histology; Humanities and Social Sciences; Immunologic Factors - pharmacology; Immunoregulation; Inflammatory bowel disease; Inflammatory bowel diseases; Inflammatory Bowel Diseases - pathology; Infliximab; Interleukin 10; Interleukin 6; Lactobacillus gasseri; Lymph nodes; Lymphocytes T; Metabolic pathways; Mice; Mice, Inbred C57BL; Monoclonal antibodies; multidisciplinary; Necrosis; Nucleic acids; Science; Science (multidisciplinary); Sodium sulfate; Synergistic effect; TNF inhibitors; Tumor Necrosis Factor-alpha - metabolism; Tumor necrosis factor-TNF; Tumor necrosis factor-α; γ-Interferon

Inflammatory bowel disease (IBD) refers to disorders involving chronic inflammation of the gastrointestinal tract. Well-established treatments for IBD have not yet to be suggested. To address this gap, we investigated the effects of co-administration of Lactobacillus gasseri ( L. gasseri ) KBL697 an...